Is Accelerate Diagnostics Stock a Good Investment?
Accelerate Diagnostics Investment Advice | AXDX |
- Examine Accelerate Diagnostics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Accelerate Diagnostics' leadership team and their track record. Good management can help Accelerate Diagnostics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Accelerate Diagnostics' business and its evolving consumer preferences.
- Compare Accelerate Diagnostics' performance and market position to its competitors. Analyze how Accelerate Diagnostics is positioned in terms of product offerings, innovation, and market share.
- Check if Accelerate Diagnostics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Accelerate Diagnostics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Accelerate Diagnostics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Accelerate Diagnostics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Accelerate Diagnostics Stock
Researching Accelerate Diagnostics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 38.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.15. Accelerate Diagnostics had not issued any dividends in recent years. The entity had 1:10 split on the 12th of July 2023.
To determine if Accelerate Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Accelerate Diagnostics' research are outlined below:
| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics has some characteristics of a very speculative penny stock | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 11.7 M. Net Loss for the year was (50.05 M) with profit before overhead, payroll, taxes, and interest of 2.89 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (24.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Accelerate Diagnostics Inc expected to post a loss of 49 cents a share - Earnings Preview - TradingView |
Accelerate Diagnostics Quarterly Liabilities And Stockholders Equity |
|
Accelerate Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Accelerate Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Accelerate Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Accelerate Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Accelerate Diagnostics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1998-05-20 | 1998-03-31 | 0.12 | 0.14 | 0.02 | 16 | ||
1997-03-17 | 1996-12-31 | 0.03 | 0.01 | -0.02 | 66 | ||
2023-05-11 | 2023-03-31 | -0.14 | -0.17 | -0.03 | 21 | ||
2016-03-09 | 2015-12-31 | -0.26 | -0.29 | -0.03 | 11 | ||
1999-06-11 | 1999-03-31 | 0.02 | -0.01 | -0.03 | 150 | ||
1999-03-04 | 1998-12-31 | 0.04 | 0.01 | -0.03 | 75 | ||
2017-02-28 | 2016-12-31 | -0.35 | -0.31 | 0.04 | 11 | ||
2016-08-08 | 2016-06-30 | -0.31 | -0.35 | -0.04 | 12 |
Know Accelerate Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Accelerate Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Accelerate Diagnostics backward and forwards among themselves. Accelerate Diagnostics' institutional investor refers to the entity that pools money to purchase Accelerate Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ghp Investment Advisors, Inc. | 2024-12-31 | 100.0 |
Accelerate Diagnostics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.27 M.Market Cap |
|
Accelerate Diagnostics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.75) | (1.66) | |
| Return On Capital Employed | 13.35 | 14.02 | |
| Return On Assets | (1.75) | (1.66) | |
| Return On Equity | 0.89 | 0.45 |
Determining Accelerate Diagnostics' profitability involves analyzing its financial statements and using various financial metrics to determine if Accelerate Diagnostics is a good buy. For example, gross profit margin measures Accelerate Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Accelerate Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Accelerate Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Accelerate Diagnostics. Check Accelerate Diagnostics' Beneish M Score to see the likelihood of Accelerate Diagnostics' management manipulating its earnings.
Evaluate Accelerate Diagnostics' management efficiency
Accelerate Diagnostics has return on total asset (ROA) of (0.6649) % which means that it has lost $0.6649 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 14.02 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.66). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 683.3 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.40) | (2.28) | |
| Tangible Book Value Per Share | (2.40) | (2.28) | |
| Enterprise Value Over EBITDA | (2.16) | (2.27) | |
| Price Book Value Ratio | (0.50) | (0.47) | |
| Enterprise Value Multiple | (2.16) | (2.27) | |
| Price Fair Value | (0.50) | (0.47) | |
| Enterprise Value | 10.1 M | 9.6 M |
Management at Accelerate Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.554 |
Basic technical analysis of Accelerate Stock
As of the 26th of March, Accelerate Diagnostics shows the mean deviation of 3.45, and Risk Adjusted Performance of (0.02). Accelerate Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Accelerate Diagnostics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Accelerate Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Accelerate Diagnostics' Outstanding Corporate Bonds
Accelerate Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Accelerate Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Accelerate bonds can be classified according to their maturity, which is the date when Accelerate Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Accelerate Diagnostics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Accelerate Diagnostics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.29 | |||
| Mean Deviation | 3.45 | |||
| Coefficient Of Variation | (3,058) | |||
| Standard Deviation | 4.66 | |||
| Variance | 21.74 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | 0.28 | |||
| Maximum Drawdown | 29.59 | |||
| Value At Risk | (6.73) | |||
| Potential Upside | 7.14 | |||
| Skewness | 0.8287 | |||
| Kurtosis | 3.13 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.29 | |||
| Mean Deviation | 3.45 | |||
| Coefficient Of Variation | (3,058) | |||
| Standard Deviation | 4.66 | |||
| Variance | 21.74 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | 0.28 | |||
| Maximum Drawdown | 29.59 | |||
| Value At Risk | (6.73) | |||
| Potential Upside | 7.14 | |||
| Skewness | 0.8287 | |||
| Kurtosis | 3.13 |
Consider Accelerate Diagnostics' intraday indicators
Accelerate Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Accelerate Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accelerate Diagnostics time-series forecasting models is one of many Accelerate Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Accelerate Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Accelerate Stock media impact
Far too much social signal, news, headlines, and media speculation about Accelerate Diagnostics that are available to investors today. That information is available publicly through Accelerate media outlets and privately through word of mouth or via Accelerate internal channels. However, regardless of the origin, that massive amount of Accelerate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Accelerate Diagnostics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Accelerate Diagnostics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Accelerate Diagnostics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Accelerate Diagnostics alpha.
Accelerate Diagnostics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Accelerate Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Accelerate Diagnostics Corporate Management
| Lawrence Mertz | Chief Officer | Profile | |
| Michael Bridge | Gen VP | Profile | |
| Laura Costa | VP Support | Profile | |
| Rita Boukamel | Senior EMEA | Profile | |
| Maya Gowri | Senior Operations | Profile |
Already Invested in Accelerate Diagnostics?
The danger of trading Accelerate Diagnostics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Accelerate Diagnostics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Accelerate Diagnostics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Accelerate Diagnostics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.